Barclays Maintains an 'Overweight' on Quest Diagnostics (DGX); Perspectives on Share Repurchase and Guidance Increase
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Quest Diagnostics (NYSE: DGX), PT $64.
Barclays analyst says, "Last night, DGX announced that it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Last night, DGX announced that it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
